Drugs / KH815
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06885645 | Apr 2025 → Jun 2027 expected | cancer | Chengdu Kanghong Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KH815 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06885645 ↗ |
| Modality | Other / unclassified | “dual-payload Antibody Drug Conjugate (ADC)” NCT06885645 ↗ |
| Route | Intravenous | “administered on Day 1 every 3 weeks via intravenous infusion” NCT06885645 ↗ |